Literature DB >> 19151762

The cell cycle checkpoint kinase CHK2 mediates DNA damage-induced stabilization of TTK/hMps1.

Y-H Yeh1, Y-F Huang, T-Y Lin, S-Y Shieh.   

Abstract

Cell cycle progression is monitored constantly to ensure faithful passage of genetic codes and genome stability. We have demonstrated previously that, upon DNA damage, TTK/hMps1 activates the checkpoint kinase CHK2 by phosphorylating CHK2 at Thr68. However, it remains to be determined whether and how TTK/hMps1 responds to DNA damage. In this report, we present evidence that TTK/hMps1 can be induced by DNA damage in normal human fibroblasts. Interestingly, the induction depends on CHK2 because CHK2-targeting small interfering RNA or a CHK2 inhibitor abolishes the increase. Such induction is mediated through phosphorylation of TTK/hMps1 at Thr288 by CHK2 and requires the CHK2 SQ/TQ cluster domain/forkhead-associated domain. In cells, TTK/hMps1 phosphorylation at Thr288 is induced by DNA damage and forms nuclear foci, which colocalize partially with gamma-H2AX. Reexpression of TTK/hMps1 T288A mutant in TTK/hMps1-knockdown cells causes a defect in G(2)/M arrest, suggesting that phosphorylation at this site participates in the proper checkpoint execution. Our study uncovered a regulatory loop between TTK/hMps1 and CHK2 whereby DNA damage-activated CHK2 may facilitate the stabilization of TTK/hMps1, therefore maintaining the checkpoint control.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19151762     DOI: 10.1038/onc.2008.477

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  24 in total

1.  Whole-Exome Sequencing Identifies the 6q12-q16 Linkage Region and a Candidate Gene, TTK, for Pulmonary Nontuberculous Mycobacterial Disease.

Authors:  Fei Chen; Eva P Szymanski; Kenneth N Olivier; Xinyue Liu; Hervé Tettelin; Steven M Holland; Priya Duggal
Journal:  Am J Respir Crit Care Med       Date:  2017-12-15       Impact factor: 21.405

2.  Activation of checkpoint kinase 2 by 3,3'-diindolylmethane is required for causing G2/M cell cycle arrest in human ovarian cancer cells.

Authors:  Prabodh K Kandala; Sanjay K Srivastava
Journal:  Mol Pharmacol       Date:  2010-05-05       Impact factor: 4.436

3.  Targeting MPS1 Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair Proteins.

Authors:  Uday Bhanu Maachani; Tamalee Kramp; Ryan Hanson; Shuping Zhao; Orieta Celiku; Uma Shankavaram; Riccardo Colombo; Natasha J Caplen; Kevin Camphausen; Anita Tandle
Journal:  Mol Cancer Res       Date:  2015-02-26       Impact factor: 5.852

4.  Phosphorylation at threonine 288 by cell cycle checkpoint kinase 2 (CHK2) controls human monopolar spindle 1 (Mps1) kinetochore localization.

Authors:  Chun-Wei Yeh; Zheng-Cheng Yu; Peng-Hsu Chen; Yu-Che Cheng; Sheau-Yann Shieh
Journal:  J Biol Chem       Date:  2014-04-24       Impact factor: 5.157

5.  UV-C irradiation delays mitotic progression by recruiting Mps1 to kinetochores.

Authors:  Xiaojuan Zhang; Youguo Ling; Wenjun Wang; Yanhong Zhang; Qingjun Ma; Pingping Tan; Ting Song; Congwen Wei; Ping Li; Xuedong Liu; Runlin Z Ma; Hui Zhong; Cheng Cao; Quanbin Xu
Journal:  Cell Cycle       Date:  2013-03-26       Impact factor: 4.534

6.  Chk2-dependent phosphorylation of myosin phosphatase targeting subunit 1 (MYPT1) regulates centrosome maturation.

Authors:  Shanshan Nai; Yingxin Shi; Huanwei Ru; Yuehe Ding; Qizhi Geng; Zhe Li; Meng-Qiu Dong; Xingzhi Xu; Jing Li
Journal:  Cell Cycle       Date:  2019-08-15       Impact factor: 4.534

Review 7.  The MPS1 family of protein kinases.

Authors:  Xuedong Liu; Mark Winey
Journal:  Annu Rev Biochem       Date:  2012-04-05       Impact factor: 23.643

8.  Mip1 associates with both the Mps1 kinase and actin, and is required for cell cortex stability and anaphase spindle positioning.

Authors:  Christopher P Mattison; Jason Stumpff; Linda Wordeman; Mark Winey
Journal:  Cell Cycle       Date:  2011-03-01       Impact factor: 4.534

9.  Characterization of novel MPS1 inhibitors with preclinical anticancer activity.

Authors:  M Jemaà; L Galluzzi; O Kepp; L Senovilla; M Brands; U Boemer; M Koppitz; P Lienau; S Prechtl; V Schulze; G Siemeister; A M Wengner; D Mumberg; K Ziegelbauer; A Abrieu; M Castedo; I Vitale; G Kroemer
Journal:  Cell Death Differ       Date:  2013-08-09       Impact factor: 15.828

10.  Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs.

Authors:  Bakhos A Tannous; Mariam Kerami; Petra M Van der Stoop; Nicholas Kwiatkowski; Jinhua Wang; Wenjun Zhou; Almuth F Kessler; Grant Lewandrowski; Lotte Hiddingh; Nik Sol; Tonny Lagerweij; Laurine Wedekind; Johanna M Niers; Marco Barazas; R Jonas A Nilsson; Dirk Geerts; Philip C De Witt Hamer; Carsten Hagemann; W Peter Vandertop; Olaf Van Tellingen; David P Noske; Nathanael S Gray; Thomas Würdinger
Journal:  J Natl Cancer Inst       Date:  2013-08-12       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.